[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"SEDECAL SA\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":137},{"warningLetters":4,"total":136},[5,31,53,74,96,117],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},871,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-05-27T04:00:00Z\">05\u002F27\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-05T04:00:00Z\">05\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsedecal-sa-707156-05052025\">Sedecal S.A.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>S. Manuel Martinez García\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sedecal S.A.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>C\u002FPelaya, 9-13 Pol Industrial Rio De Janeiro\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>28110\u003C\u002Fspan> \u003Cspan>ALGETE\u003C\u002Fspan> \u003Cspan>Madrid\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Spain\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mmartinez@sedecal.com\"> mmartinez@sedecal.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mmartinezjr@sedecal.com\"> mmartinezjr@sedecal.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 5, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Martinez García:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Madrid, Spain on January 20, 2025, through January 24, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures DX-D 100, DX-D 600, and MobileDiagnost wDR systems. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received a response from Maria Luisa Gomez de Aguero, Director of Quality and Regulatory Affairs dated February 14, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish and maintain procedures for implementing corrective and preventative action (CAPA), as required by 21 CFR 820.100(a). Specifically, your firm initiated CAPA 20\u002F028 to address customer complaints reporting DXD100 mobile x-ray units self-propelling crashing into x-ray control panel in one case and almost running into the patient, in the other case. This issue affects all mobile x-ray unit models. However, your firm failed to document an assessment of the risk of the affected units in the field for this issue, when investigating the cause of nonconformities relating to the product.\u003C\u002Fp>\u003Cp>We reviewed your response and conclude that the adequacy of your firm’s response cannot be determined at this time. You stated that you will revise procedures PG-031 Customer complaint and PG-020 Risk management procedures to ensure that an investigation is documented properly. You also stated that you will revise procedure PG-019 Corrective and Preventive action and conduct training for the relevant personnel. Although your firm’s response states you will revise the relevant procedures, the revised procedures were not included in the response for evaluation. Your firm’s response does not include a retrospective review of related documentation to ensure compliance with the updated procedures and how these will be implemented moving forward. Documentation of corrective action, retrospective review as well as training is needed in order to adequately address this observation.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Design validation shall include risk analysis, where appropriate. Specifically, your firm conducted a recall to address unintended movement of MobileDiagnost wDR that could result in life threatening situations and cause the device to stop working as intended. However, the risk analysis for MobileDiagnost wDR (Document IH0532RA_Annex, dated April 26, 2022) fails to include this increased hazard severity (life threatening) to ensure that appropriate risk control measures are implemented.\u003C\u002Fp>\u003Cp>We reviewed your response and conclude that the adequacy of your firm’s response cannot be determined at this time. Your response states that you will re-evaluate and document the risk analysis for the recall. You also state that you will revise procedures PG-031 Customer complaint and PG-020 Risk management procedures to account for risk analysis. Although your firm’s response states you will revise the relevant procedures, the revised procedures were not included in the response for evaluation. Your firm’s response does not include a retrospective review of related documentation to ensure compliance with the updated procedures and how these will be implemented moving forward. Documentation of corrective action, retrospective review as well as training is needed in order to adequately address this observation.\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s DX-D100 devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Device; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>3. Failure to submit a written report of a correction or removal of a device to FDA, initiated to reduce a risk to health or to remedy a violation which may present a risk to health, as required by 21 CFR 806.10. Specifically, your firm initiated CAPA 20\u002F028 to address customer complaints reporting DXD100 mobile x-ray units self-propelling crashing into x-ray control panel in one case and almost running into the patient, in the other case. This issue affects all mobile x-ray unit models. Your firm implemented two corrective actions to address this issue and issued a service note to be distributed to customers. However, your firm failed to submit a report of correction or removal to FDA for these actions.\u003C\u002Fp>\u003Cp>We reviewed your response to Observation 1 and conclude it is not adequate. Your investigation of the issue concluded that this issue does not pose a risk to safety due to the low speed of the movement and did not consider it as a reportable recall. However, your firm implemented two corrections to address this issue and issued a service note to be distributed to the customers. Our assessment concluded that the unintended movement presents a risk to health and your firm’s actions were initiated to reduce the risk to health.\u003C\u002Fp>\u003Cp>Your firm’s devices are also electronic products subject to compliance with Subchapter C of the Act, Electronic Product Radiation Control, the requirements at 21 CFR 1000-1005, and the performance standards at 21 CFR 1020.30 and 1020.31. Your firm failed to comply with the regulations regarding reporting and recordkeeping.\u003C\u002Fp>\u003Cp>4. Failure to conduct certification of an electronic product, based upon a testing program which is in accordance with good manufacturing practices, as required by 21 CFR 1002.30(a)(1). Specifically, a review of the design control records revealed that the wDR2.2 was approved and released for distribution in the US without documentation to show that the required performance standard checklist (Technical Report Subchapter J of 21 CFR MobileDiagnost wDR 2.2, Doc #R01005_21CKL) was completed to demonstrate compliance with the performance standard requirements prior to release of the product. The performance standard checklist was not completed until Jan. 14, 2025.\u003C\u002Fp>\u003Cp>We reviewed your response and conclude that the adequacy of your firm’s response cannot be determined at this time. You stated that you will review and revise procedures PE-062 Design Verification, PG-044 Organization of Project Teams among others. Although your firm’s response states you will revise the relevant procedures, the revised procedures were not included in the response for evaluation. Your firm’s response does not include a retrospective review of related documentation to ensure compliance with the updated procedures. Documentation of corrective action, retrospective review as well as training is needed in order to adequately address this observation.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case 707156 when replying. If you have any questions about the contents of this letter, please contact: Lu Jiang at +1(240)402-5779.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Robert Ochs, Ph.D.\u003Cbr>Director\u003Cbr>OHT8: Office of Radiological Health\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Devan Moser\u003Cbr>U.S. Agent\u003Cbr>Sedecal USA Inc.\u003Cbr>7555 N. Caldwell Avenue\u003Cbr>Niles, Illinois 60714\u003Cbr>dmoser@sedecalusa.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nS. Manuel Martinez García\n\nRecipient Title\n\nPresident and CEO\n\nSedecal S.A.\n\nC\u002FPelaya, 9-13 Pol Industrial Rio De Janeiro\n\n28110 ALGETE Madrid\n\nSpain\n\nmmartinez@sedecal.com\n\nmmartinezjr@sedecal.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nMay 5, 2025\nDear Mr. Martinez García:\nDuring an inspection of your firm located in Madrid, Spain on January 20, 2025, through January 24, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures DX-D 100, DX-D 600, and MobileDiagnost wDR systems. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Maria Luisa Gomez de Aguero, Director of Quality and Regulatory Affairs dated February 14, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish and maintain procedures for implementing corrective and preventative action (CAPA), as required by 21 CFR 820.100(a). Specifically, your firm initiated CAPA 20\u002F028 to address customer complaints reporting DXD100 mobile x-ray units self-propelling crashing into x-ray control panel in one case and almost running into the patient, in the other case. This issue affects all mobile x-ray unit models. However, your firm failed to document an assessment of the risk of the affected units in the field for this issue, when investigating the cause of nonconformities relating to the product.\nWe reviewed your response and conclude that the adequacy of your firm’s response cannot be determined at this time. You stated that you will revise procedures PG-031 Customer complaint and PG-020 Risk management procedures to ensure that an investigation is documented properly. You also stated that you will revise procedure PG-019 Corrective and Preventive action and conduct training for the relevant personnel. Although your firm’s response states you will revise the relevant procedures, the revised procedures were not included in the response for evaluation. Your firm’s response does not include a retrospective review of related documentation to ensure compliance with the updated procedures and how these will be implemented moving forward. Documentation of corrective action, retrospective review as well as training is needed in order to adequately address this observation.\n2. Failure to adequately establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). Design validation shall include risk analysis, where appropriate. Specifically, your firm conducted a recall to address unintended movement of MobileDiagnost wDR that could result in life threatening situations and cause the device to stop working as intended. However, the risk analysis for MobileDiagnost wDR (Document IH0532RA_Annex, dated April 26, 2022) fails to include this increased hazard severity (life threatening) to ensure that appropriate risk control measures are implemented.\nWe reviewed your response and conclude that the adequacy of your firm’s response cannot be determined at this time. Your response states that you will re-evaluate and document the risk analysis for the recall. You also state that you will revise procedures PG-031 Customer complaint and PG-020 Risk management procedures to account for risk analysis. Although your firm’s response states you will revise the relevant procedures, the revised procedures were not included in the response for evaluation. Your firm’s response does not include a retrospective review of related documentation to ensure compliance with the updated procedures and how these will be implemented moving forward. Documentation of corrective action, retrospective review as well as training is needed in order to adequately address this observation.\nOur inspection also revealed that your firm’s DX-D100 devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Device; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\n3. Failure to submit a written report of a correction or removal of a device to FDA, initiated to reduce a risk to health or to remedy a violation which may present a risk to health, as required by 21 CFR 806.10. Specifically, your firm initiated CAPA 20\u002F028 to address customer complaints reporting DXD100 mobile x-ray units self-propelling crashing into x-ray control panel in one case and almost running into the patient, in the other case. This issue affects all mobile x-ray unit models. Your firm implemented two corrective actions to address this issue and issued a service note to be distributed to customers. However, your firm failed to submit a report of correction or removal to FDA for these actions.\nWe reviewed your response to Observation 1 and conclude it is not adequate. Your investigation of the issue concluded that this issue does not pose a risk to safety due to the low speed of the movement and did not consider it as a reportable recall. However, your firm implemented two corrections to address this issue and issued a service note to be distributed to the customers. Our assessment concluded that the unintended movement presents a risk to health and your firm’s actions were initiated to reduce the risk to health.\nYour firm’s devices are also electronic products subject to compliance with Subchapter C of the Act, Electronic Product Radiation Control, the requirements at 21 CFR 1000-1005, and the performance standards at 21 CFR 1020.30 and 1020.31. Your firm failed to comply with the regulations regarding reporting and recordkeeping.\n4. Failure to conduct certification of an electronic product, based upon a testing program which is in accordance with good manufacturing practices, as required by 21 CFR 1002.30(a)(1). Specifically, a review of the design control records revealed that the wDR2.2 was approved and released for distribution in the US without documentation to show that the required performance standard checklist (Technical Report Subchapter J of 21 CFR MobileDiagnost wDR 2.2, Doc #R01005_21CKL) was completed to demonstrate compliance with the performance standard requirements prior to release of the product. The performance standard checklist was not completed until Jan. 14, 2025.\nWe reviewed your response and conclude that the adequacy of your firm’s response cannot be determined at this time. You stated that you will review and revise procedures PE-062 Design Verification, PG-044 Organization of Project Teams among others. Although your firm’s response states you will revise the relevant procedures, the revised procedures were not included in the response for evaluation. Your firm’s response does not include a retrospective review of related documentation to ensure compliance with the updated procedures. Documentation of corrective action, retrospective review as well as training is needed in order to adequately address this observation.\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case 707156 when replying. If you have any questions about the contents of this letter, please contact: Lu Jiang at +1(240)402-5779.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nRobert Ochs, Ph.D.\nDirector\nOHT8: Office of Radiological Health\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nDevan Moser\nU.S. Agent\nSedecal USA Inc.\n7555 N. Caldwell Avenue\nNiles, Illinois 60714\ndmoser@sedecalusa.com","Sedecal S.A.","sedecal-sa-707156-05052025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsedecal-sa-707156-05052025","2026-10-26T08:09:55.130548+00:00","Warning Letter","Issued","2025-05-27","707156","Medical Devices","S. Manuel Martinez García","2026-08-19T16:44:48.776+00:00","Via Email","2025-05-05",{"id":32,"raw":33,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},3703,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-08T04:00:00Z\">06\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdh-medical-services-728238-06082026\">D&amp;H Medical Services\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>D&amp;H Medical Services\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2500 NW 79th Avenue, Suite 265\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Doral\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33122\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@dhmedicalcenter.com\"> info@dhmedicalcenter.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: MARCS-CMS 728238\u003C\u002Fp>\u003Cp>To D&amp;H Medical Services:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of D&amp;H Medical Services’ website, https:\u002F\u002Fwww.dhmedicalcenter.com, FDA Establishment Identifier (FEI) 3044174854, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&amp;C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&amp;C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>More specifically,\u003C\u002Fp>\u003Cp>1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Same ingredient as Ozempic®”\u003C\u002Fli>\u003Cli>“Same ingredient as Rybelsus®”\u003C\u002Fli>\u003Cli>“Same ingredient as Mounjaro®”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\u003C\u002Fp>\u003Cp>Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&amp;C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&amp;C Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728238 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\u003C\u002Fp>\u003Cp>1. Identifying the entities that produce the compounded drug products offered on your website;\u003C\u002Fp>\u003Cp>2. Providing a representative sample of labeling for such drug products; and\u003C\u002Fp>\u003Cp>3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&amp;C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash, JD\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>________________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nD&H Medical Services\n\n2500 NW 79th Avenue, Suite 265\n\nDoral, FL 33122\n\nUnited States\n\ninfo@dhmedicalcenter.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nReference number: MARCS-CMS 728238\nTo D&H Medical Services:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of D&H Medical Services’ website, https:\u002F\u002Fwww.dhmedicalcenter.com, FDA Establishment Identifier (FEI) 3044174854, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nYour representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\nMore specifically,\n1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“Same ingredient as Ozempic®”\n“Same ingredient as Rybelsus®”\n“Same ingredient as Mounjaro®”\nCompounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\nAccordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)].\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&C Act, including the new drug approval requirements.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728238 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\n1. Identifying the entities that produce the compounded drug products offered on your website;\n2. Providing a representative sample of labeling for such drug products; and\n3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\nPlease note FDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash, JD\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n________________________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.","D&H Medical Services","dh-medical-services-728238-06082026","2026-08-19T04:06:48.349905+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdh-medical-services-728238-06082026","2026-10-26T08:08:24.115003+00:00","2026-06-16","728238","Drugs","2026-08-19T04:34:50.914+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-06-08",{"id":54,"raw":55,"subject":59,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":18,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":19,"issuing_office":37,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":72,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},527,[56,57,58,37,59,13,13,13],"\u003Ctime datetime=\"2025-10-21T04:00:00Z\">10\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-17T04:00:00Z\">09\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrs-analytical-services-llc-711133-09172025\">BRS Analytical Services, LLC\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-112\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Teresa L. Bandrowsky\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>BRS Analytical Services, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11697 Lakeside Crossing Court\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>St. Louis\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63146-8606\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-112\u003C\u002Fp>\u003Cp>September 17, 2025\u003C\u002Fp>\u003Cp>Dear Ms. Bandrowsky:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility and contract testing laboratory, BRS Analytical Services, LLC, FEI 3023604380, at 11697 Lakeside Crossing Court, St. Louis, from March 10 to 26, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 14, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas. Your firm also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.42(c)(10) and 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Cleanroom Design\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your ISO 5 area used for aseptic compounding and filling sterile over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products was fundamentally unsuitable for its intended use. For example, your ISO 5 area had gaps in the wall intended to separate it from the immediately surrounding unclassified warehouse, including large gaps between most wall sections and the floor. Some of these gaps contained mesh screens that appeared to be dirty. Furthermore, you failed to maintain an adequate differential pressure between the ISO 5 area and the warehouse, and did not continuously monitor that pressure. The lack of both physical and aerodynamic segregation in your aseptic processing facility design posed an unacceptable risk to product sterility.\u003C\u002Fp>\u003Cp>The ISO 5 area is critical because sterile drug products are exposed and are therefore vulnerable to contamination. Your aseptic manufacturing facility, equipment, and process must be designed, and operations must be executed, to minimize contamination hazards to your sterile drug product. The unacceptable design of your operation precluded the ability to maintain asepsis.\u003C\u002Fp>\u003Cp>\u003Cem>Environmental Monitoring\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to establish an adequate system for monitoring environmental conditions. For example, you did not routinely perform viable air monitoring during production, despite a procedural requirement to do so. In addition, your nonviable particle monitor was placed on top of the enclosed cabinet in which filling occurred instead of inside it, rendering the resulting data non-representative of the environmental conditions near the areas of critical exposure on the aseptic processing line. Finally, you failed to routinely review environmental monitoring data prior to batch release.\u003C\u002Fp>\u003Cp>Vigilant and responsive environmental and personnel monitoring programs provide meaningful information on the state of control of the aseptic processing operation, and enable an early warning system that identifies emerging contamination hazards before sterility is compromised. Operations that include highly \u003Cstrong>(b)(4)\u003C\u002Fstrong> intensive aseptic activities warrant a more extensive environmental and personnel monitoring program, including but not limited to an emphasis on increased sampling that monitors ongoing batch production conditions more extensively.\u003C\u002Fp>\u003Cp>\u003Cem>Facility Maintenance Deficiencies\u003C\u002Fem>\u003C\u002Fp>\u003Cp>During the inspection, we observed your facility to be in a state of disrepair or unclean in several instances. This includes, but is not limited to, the following deficiencies within your aseptic processing room:\u003C\u002Fp>\u003Cp>• Discoloration and apparent residue on light panels above the aseptic filling equipment during operations.\u003Cbr>• Chipped paint on a floor scale.\u003Cbr>• Discoloration on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilizer and a table.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Poor Aseptic Behavior\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We observed poor practices in ISO 5 areas during your \u003Cstrong>(b)(4)\u003C\u002Fstrong> intensive aseptic processing of sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products, including but not limited to:\u003C\u002Fp>\u003Cp>• Operators blocked unidirectional airflow during routine production by placing their gloved hands and hooded, masked heads directly over open sterilized bottles.\u003Cbr>• The skin surrounding operators’ safety glasses was exposed in the ISO 5 area.\u003Cbr>• Use of nonsterile face masks.\u003Cbr>• Use of nonsterile paper towels in the ISO 5 area, including inside the filling cabinet.\u003Cbr>• Failure to seal a vessel containing sterile drug product. Instead of a securely fitted cap, you used an \u003Cstrong>(b)(4)\u003C\u002Fstrong> intended to cover an open port in the sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> holding tank in the ISO 5 area during the filling process, which was typically run for \u003Cstrong>(b)(4)\u003C\u002Fstrong> days and did not include additional sterilizing \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, our investigators observed condensation inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as well as air gaps that provided an avenue for ingress of \u003Cstrong>(b)(4)\u003C\u002Fstrong> air.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Media Fill Program\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your media fills failed to accurately simulate commercial operations. You only incubated approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> of units for each media fill, rather than \u003Cstrong>(b)(4)\u003C\u002Fstrong> units. In contrast, your protocols required \u003Cstrong>(b)(4)\u003C\u002Fstrong> units that passed inspection to be incubated. In addition, each media fill lasted only approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> or less, although your commercial aseptic filling operations typically lasted \u003Cstrong>(b)(4)\u003C\u002Fstrong> days.\u003C\u002Fp>\u003Cp>It is essential that \u003Cstrong>(b)(4)\u003C\u002Fstrong> media fill units be incubated and examined for evidence of microbial contamination. Also, to accurately simulate contamination risks, the duration of the process simulation for \u003Cstrong>(b)(4)\u003C\u002Fstrong> intensive lines normally should be no less than the length of the actual manufacturing process.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Assurance of Sterilization\u003C\u002Fem>\u003C\u002Fp>\u003Cp>• The validation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process used to sterilize direct product contact parts, including transfer hoses and sterilizing \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was inadequate. For example, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization validation process did not include the use of biological indicators. Instead, \u003Cstrong>(b)(4)\u003C\u002Fstrong> water was placed in jars and tested for sterility. Notably, one of these jars of water tested positive for growth, but you did not conduct an investigation.\u003Cbr>• Sterilizing \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not integrity tested for each batch of drug products manufactured.\u003C\u002Fp>\u003Cp>It is essential that product contact equipment is sterile to be suitable for its intended use. Sterilization cycle validation is established through studies that incorporate rigorous physical and biological measurements. Between uses, sterile equipment must be held under ISO 5 conditions and continuously maintained in a manner that prevents contamination.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Smoke Study\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your smoke study did not adequately demonstrate unidirectional air flow in the ISO 5 area that was used for the aseptic filling of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products. For example:\u003C\u002Fp>\u003Cp>• Your smoke study did not evaluate unidirectionality. Instead, you turned off the HEPA-\u003Cstrong>(b)(4)\u003C\u002Fstrong> fans, filled the ISO 5 area with smoke, then turned the fans on and verified that the room was cleared of smoke.\u003Cbr>• You failed to conduct a smoke study with your actual filling equipment present.\u003Cbr>• Your smoke study was not conducted under dynamic conditions.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to maintain adequate CGMP oversight and allowed the distribution of sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products manufactured under unacceptable conditions, which included poorly designed facilities, an unsuitable aseptic manufacturing process, and deficient environmental monitoring. You also failed to ensure implementation of an effective qualification and validation program, and perform adequate antimicrobial effectiveness studies for your multi-dose aqueous-based sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products.\u003C\u002Fp>\u003Cp>In addition, you failed to ensure that adequate procedures were followed describing the roles and responsibilities of the QU including, but not limited to, raw material supplier qualification.\u003C\u002Fp>\u003Cp>Significant findings in this letter indicate that your QU was not fully exercising its authority or responsibility. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On April 17, 2025, FDA held a teleconference with you recommending that you remove from the U.S. market all batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products currently in distribution. On April 21, 2025, you committed to ceasing the manufacture and distribution of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products and agreed to a voluntary recall of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products currently in distribution in the U.S. On April 23, 2025, you issued a voluntary recall of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products due to CGMP deviations and lack of assurance of sterility. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002F?Event=96741.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment dated June 24, 2025, to permanently cease production of all drugs at this facility.\u003C\u002Fp>\u003Cp>Notify this office if you intend to resume your drug manufacturing operations at this site or in another location. You are responsible for resolving all deficiencies and systemic flaws to ensure that your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective actions and preventive actions (CAPA).\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3023604380 and ATTN: Russell Riley.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>Cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>(b)(6), (b)(7)(C)\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\u003Cp>_____________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-25-112\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMs. Teresa L. Bandrowsky\n\nRecipient Title\n\nOwner\n\nBRS Analytical Services, LLC\n\n11697 Lakeside Crossing Court\n\nSt. Louis, MO 63146-8606\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-112\nSeptember 17, 2025\nDear Ms. Bandrowsky:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility and contract testing laboratory, BRS Analytical Services, LLC, FEI 3023604380, at 11697 Lakeside Crossing Court, St. Louis, from March 10 to 26, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 14, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas. Your firm also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.42(c)(10) and 211.63).\nCleanroom Design\nYour ISO 5 area used for aseptic compounding and filling sterile over-the-counter (OTC) (b)(4) drug products was fundamentally unsuitable for its intended use. For example, your ISO 5 area had gaps in the wall intended to separate it from the immediately surrounding unclassified warehouse, including large gaps between most wall sections and the floor. Some of these gaps contained mesh screens that appeared to be dirty. Furthermore, you failed to maintain an adequate differential pressure between the ISO 5 area and the warehouse, and did not continuously monitor that pressure. The lack of both physical and aerodynamic segregation in your aseptic processing facility design posed an unacceptable risk to product sterility.\nThe ISO 5 area is critical because sterile drug products are exposed and are therefore vulnerable to contamination. Your aseptic manufacturing facility, equipment, and process must be designed, and operations must be executed, to minimize contamination hazards to your sterile drug product. The unacceptable design of your operation precluded the ability to maintain asepsis.\nEnvironmental Monitoring\nYou failed to establish an adequate system for monitoring environmental conditions. For example, you did not routinely perform viable air monitoring during production, despite a procedural requirement to do so. In addition, your nonviable particle monitor was placed on top of the enclosed cabinet in which filling occurred instead of inside it, rendering the resulting data non-representative of the environmental conditions near the areas of critical exposure on the aseptic processing line. Finally, you failed to routinely review environmental monitoring data prior to batch release.\nVigilant and responsive environmental and personnel monitoring programs provide meaningful information on the state of control of the aseptic processing operation, and enable an early warning system that identifies emerging contamination hazards before sterility is compromised. Operations that include highly (b)(4) intensive aseptic activities warrant a more extensive environmental and personnel monitoring program, including but not limited to an emphasis on increased sampling that monitors ongoing batch production conditions more extensively.\nFacility Maintenance Deficiencies\nDuring the inspection, we observed your facility to be in a state of disrepair or unclean in several instances. This includes, but is not limited to, the following deficiencies within your aseptic processing room:\n• Discoloration and apparent residue on light panels above the aseptic filling equipment during operations.\n• Chipped paint on a floor scale.\n• Discoloration on the (b)(4) sterilizer and a table.\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nPoor Aseptic Behavior\nWe observed poor practices in ISO 5 areas during your (b)(4) intensive aseptic processing of sterile (b)(4) drug products, including but not limited to:\n• Operators blocked unidirectional airflow during routine production by placing their gloved hands and hooded, masked heads directly over open sterilized bottles.\n• The skin surrounding operators’ safety glasses was exposed in the ISO 5 area.\n• Use of nonsterile face masks.\n• Use of nonsterile paper towels in the ISO 5 area, including inside the filling cabinet.\n• Failure to seal a vessel containing sterile drug product. Instead of a securely fitted cap, you used an (b)(4) intended to cover an open port in the sterile (b)(4) holding tank in the ISO 5 area during the filling process, which was typically run for (b)(4) days and did not include additional sterilizing (b)(4). In addition, our investigators observed condensation inside the (b)(4), as well as air gaps that provided an avenue for ingress of (b)(4) air.\nInadequate Media Fill Program\nYour media fills failed to accurately simulate commercial operations. You only incubated approximately (b)(4) of units for each media fill, rather than (b)(4) units. In contrast, your protocols required (b)(4) units that passed inspection to be incubated. In addition, each media fill lasted only approximately (b)(4) or less, although your commercial aseptic filling operations typically lasted (b)(4) days.\nIt is essential that (b)(4) media fill units be incubated and examined for evidence of microbial contamination. Also, to accurately simulate contamination risks, the duration of the process simulation for (b)(4) intensive lines normally should be no less than the length of the actual manufacturing process.\nInadequate Assurance of Sterilization\n• The validation of the (b)(4) sterilization process used to sterilize direct product contact parts, including transfer hoses and sterilizing (b)(4), was inadequate. For example, the (b)(4) sterilization validation process did not include the use of biological indicators. Instead, (b)(4) water was placed in jars and tested for sterility. Notably, one of these jars of water tested positive for growth, but you did not conduct an investigation.\n• Sterilizing (b)(4) were not integrity tested for each batch of drug products manufactured.\nIt is essential that product contact equipment is sterile to be suitable for its intended use. Sterilization cycle validation is established through studies that incorporate rigorous physical and biological measurements. Between uses, sterile equipment must be held under ISO 5 conditions and continuously maintained in a manner that prevents contamination.\nInadequate Smoke Study\nYour smoke study did not adequately demonstrate unidirectional air flow in the ISO 5 area that was used for the aseptic filling of (b)(4) drug products. For example:\n• Your smoke study did not evaluate unidirectionality. Instead, you turned off the HEPA-(b)(4) fans, filled the ISO 5 area with smoke, then turned the fans on and verified that the room was cleared of smoke.\n• You failed to conduct a smoke study with your actual filling equipment present.\n• Your smoke study was not conducted under dynamic conditions.\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22)\nYour quality unit (QU) failed to maintain adequate CGMP oversight and allowed the distribution of sterile (b)(4) drug products manufactured under unacceptable conditions, which included poorly designed facilities, an unsuitable aseptic manufacturing process, and deficient environmental monitoring. You also failed to ensure implementation of an effective qualification and validation program, and perform adequate antimicrobial effectiveness studies for your multi-dose aqueous-based sterile (b)(4) drug products.\nIn addition, you failed to ensure that adequate procedures were followed describing the roles and responsibilities of the QU including, but not limited to, raw material supplier qualification.\nSignificant findings in this letter indicate that your QU was not fully exercising its authority or responsibility. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\nDrug Recall\nOn April 17, 2025, FDA held a teleconference with you recommending that you remove from the U.S. market all batches of (b)(4) drug products currently in distribution. On April 21, 2025, you committed to ceasing the manufacture and distribution of all (b)(4) drug products and agreed to a voluntary recall of all (b)(4) drug products currently in distribution in the U.S. On April 23, 2025, you issued a voluntary recall of all (b)(4) drug products due to CGMP deviations and lack of assurance of sterility. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002F?Event=96741.\nDrug Production Ceased\nWe acknowledge your commitment dated June 24, 2025, to permanently cease production of all drugs at this facility.\nNotify this office if you intend to resume your drug manufacturing operations at this site or in another location. You are responsible for resolving all deficiencies and systemic flaws to ensure that your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective actions and preventive actions (CAPA).\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive (b)(4)1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3023604380 and ATTN: Russell Riley.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nCc: (b)(4)\n(b)(6), (b)(7)(C)\n_____________\n1 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","BRS Analytical Services, LLC","brs-analytical-services-llc-711133-09172025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbrs-analytical-services-llc-711133-09172025","2026-10-26T08:08:09.185449+00:00","2025-10-21","711133","Drugs Over-the-Counter Drugs","Ms. Teresa L. Bandrowsky","2026-08-19T16:13:17.32+00:00","VIA EMAIL WITH READ RECEIPT","320-25-112","2025-09-17",{"id":75,"raw":76,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":18,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":90,"closeout_date":19,"issuing_office":80,"recipient_name":91,"body_fetched_at":92,"delivery_method":93,"recipient_title":19,"reference_number":94,"action_taken_date":95,"medical_device_id":19,"response_letter_date":19},543,[77,78,79,80,81,13,13,13],"\u003Ctime datetime=\"2025-10-07T04:00:00Z\">10\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-24T04:00:00Z\">09\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-life-medical-services-llc-711102-09242025\">New Life Medical Services, LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","CGMP\u002FDeviations\u002FBiologics License Application (BLA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 25-711102\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joshua M. Mansavage\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>New Life Medical Services, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>244 Crystal Grove Blvd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lutz\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33548-6460\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Joshm@newliferegen.com\"> Joshm@newliferegen.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 24, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 25- 711102\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Mansavage:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between May 14, 2024, and May 20, 2024. During the inspection, FDA documented that your company sells human products derived from umbilical cord (Restor+\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>, Regain, and Renyte), an amniotic fluid derived product (ReCyte\u002FCytosomes\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>), and an exosome product (also referred to as an “extracellular vesicle” product, named Rexo) for allogeneic use (collectively, “your products”).\u003C\u002Fp>\u003Cp>This letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. §355(a). Your products are also unlicensed biological products in violation of section351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved undersection 351(a) of the PHS Act is not required to have an approved application undersection 505 of the FD&amp;C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website, www.newliferegen.com, (last visited September 2025) and your Instagram page (newliferegen, last visited September 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your website states that “Restor+ facilitates healing by secreting powerful bioactive molecules, creating an optimal environment for tissue repair and regeneration.”\u003C\u002Fli>\u003Cli>Your Physician Guide states Restor+ “has a strong anti-inflammatory effect reducing the expression of inflammatory cytokines.”\u003C\u002Fli>\u003Cli>Your training videos demonstrate use of Restor+, occasionally in conjunction with Rexo, in the treatment of several conditions, including neuropathy and bone spurs, as well as treating pain and inflammation.\u003C\u002Fli>\u003Cli>Your package insert for Regain states it is intended “to supplement the recipient’s tissue and assist in the body’s natural regenerative functions.”\u003C\u002Fli>\u003Cli>Your Physician Guide states:\u003Cbr>o “Higher concentration of growth factors in Renyte act as anti-inflammatory and have been shown to prevent cell death.”\u003Cbr>o Renyte is intended to “supplement or replace damaged or inadequate connective tissue.”\u003C\u002Fli>\u003Cli>Your product update for Cytosomes to ReCyte indicates that “Recyte is intended to help with inflammation and to enhance the healing process.”\u003C\u002Fli>\u003Cli>Your website states that “Rexo is an innovative extracellular vesicle product derived from Wharton’s Jelly that offers advanced healing properties.”\u003C\u002Fli>\u003Cli>One of your Instagram posts states, “Flagship Products … Restor+ and Rexo … Ideal Applications” and lists orthopedic procedures, paraspinal treatments, hair restoration therapies, and neuropathy interventions.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In addition, evidence obtained during the inspection documents your representation that, “[New Life Medical Services] products across the board are utilized for pain management, inflammation of soft tissue, … and non-union fractures. ‘The application for all products are copy, paste.’”\u003C\u002Fp>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your Restor+, Regain, and Renyte products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, New Life Medical Services does not qualify for any exception in 21 CFR 1271.15, and Restor+, Regain, and Renyte fail to meet all criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your Restor+, Regain, and Renyte products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because the processing alters the original relevant characteristics of the umbilical cord tissue related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>In addition, your Restor+, Regain, and Renyte products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord). Rather, your products are intended for use in healing\u002Fsupplementing tissue, orthopedic procedures, treating neuropathy, and reduction of inflammation which are not basic functions of umbilical cord in the donor.\u003C\u002Fp>\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your Restor+, Regain, and Renyte products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Subject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Concerns\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition to the violations described above, we have concerns about the following products:\u003C\u002Fp>\u003Cul>\u003Cli>FDA’s review of your website and other records found that you market additional products, an umbilical cord derived product named Restor Charge and an exosome-based product named Rexo Charge\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Based on our review, these products are drugs and\u002For biological products, which are subject to premarket review and approval requirements. In your response, please provide a customer list for each of these products and indicate whether you believe you sell them in compliance with the FD&amp;C Act. If so, include your explanation why; if not, include your plan for coming into compliance.\u003C\u002Fli>\u003Cli>We also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Restor+ is also referred to as restor+, restor, Restor, Restor Plus Wharton’s Jelly, and Restor+ Wharton’s Jelly.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> You explained during the inspection that the product Cytosomes was renamed Recyte in 2023 and provided a “Product Update” that states “Cytosomes gets a new name recyte®[.] New name, same quality product.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Because Restor+, Regain, and Renyte fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Your Instagram post from December 19, 2024, states that “Restor Charge and Rexo Charge provide strong healing potential at a lower price, making regenerative treatments accessible for everyone.”\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 25-711102\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJoshua M. Mansavage\n\nRecipient Title\n\nChief Executive Officer\n\nNew Life Medical Services, LLC\n\n244 Crystal Grove Blvd\n\nLutz, FL 33548-6460\n\nUnited States\n\nJoshm@newliferegen.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nSeptember 24, 2025\nCBER 25- 711102\nDear Mr. Mansavage:\nThe United States Food and Drug Administration (FDA) inspected your facility, located at the above address, between May 14, 2024, and May 20, 2024. During the inspection, FDA documented that your company sells human products derived from umbilical cord (Restor+1, Regain, and Renyte), an amniotic fluid derived product (ReCyte\u002FCytosomes2), and an exosome product (also referred to as an “extracellular vesicle” product, named Rexo) for allogeneic use (collectively, “your products”).\nThis letter is to advise you that your products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §355(a). Your products are also unlicensed biological products in violation of section351(a)(1) of the Public Health Service Act (PHS Act), 42 U.S.C. § 262(a)(1). A biological product for which a biologics license application (BLA) has been approved undersection 351(a) of the PHS Act is not required to have an approved application undersection 505 of the FD&C Act, 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nBased on information and records reviewed by FDA, including your website, www.newliferegen.com, (last visited September 2025) and your Instagram page (newliferegen, last visited September 2025), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example:\nYour website states that “Restor+ facilitates healing by secreting powerful bioactive molecules, creating an optimal environment for tissue repair and regeneration.”\nYour Physician Guide states Restor+ “has a strong anti-inflammatory effect reducing the expression of inflammatory cytokines.”\nYour training videos demonstrate use of Restor+, occasionally in conjunction with Rexo, in the treatment of several conditions, including neuropathy and bone spurs, as well as treating pain and inflammation.\nYour package insert for Regain states it is intended “to supplement the recipient’s tissue and assist in the body’s natural regenerative functions.”\nYour Physician Guide states:\no “Higher concentration of growth factors in Renyte act as anti-inflammatory and have been shown to prevent cell death.”\no Renyte is intended to “supplement or replace damaged or inadequate connective tissue.”\nYour product update for Cytosomes to ReCyte indicates that “Recyte is intended to help with inflammation and to enhance the healing process.”\nYour website states that “Rexo is an innovative extracellular vesicle product derived from Wharton’s Jelly that offers advanced healing properties.”\nOne of your Instagram posts states, “Flagship Products … Restor+ and Rexo … Ideal Applications” and lists orthopedic procedures, paraspinal treatments, hair restoration therapies, and neuropathy interventions.\nIn addition, evidence obtained during the inspection documents your representation that, “[New Life Medical Services] products across the board are utilized for pain management, inflammation of soft tissue, … and non-union fractures. ‘The application for all products are copy, paste.’”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i).\nYour Restor+, Regain, and Renyte products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a) are not regulated solely under section 361 of the PHS Act and the regulations in 21 CFR part 1271. Unless an exception in 21 CFR 1271.15 applies, such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act and are subject to additional regulation, including applicable premarket review. Based on a review of relevant materials, New Life Medical Services does not qualify for any exception in 21 CFR 1271.15, and Restor+, Regain, and Renyte fail to meet all criteria in 21 CFR 1271.10(a).\nFor example, your Restor+, Regain, and Renyte products fail to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1), because the processing alters the original relevant characteristics of the umbilical cord tissue related to its utility for reconstruction, repair, or replacement. The processing of the umbilical cord from the form of a conduit into an injectable form, significantly alters the physical state of the HCT\u002FP. The umbilical cord is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nIn addition, your Restor+, Regain, and Renyte products fail to meet the criterion that the HCT\u002FPs be “intended for homologous use only,” which means that the “labeling, advertising, or other indications of the manufacturer’s objective intent” demonstrate that the HCT\u002FP is intended to perform “the same basic function or functions in the recipient as in the donor” (21 CFR 1271.3(c) and 1271.10(a)(2)). Your product is not intended solely to perform the same basic function or functions of the HCT\u002FP in the recipient as in the donor (e.g., serving as a conduit for umbilical cord). Rather, your products are intended for use in healing\u002Fsupplementing tissue, orthopedic procedures, treating neuropathy, and reduction of inflammation which are not basic functions of umbilical cord in the donor.\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.3 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your Restor+, Regain, and Renyte products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nSubject to certain exceptions not applicable here, to lawfully introduce or deliver for introduction into interstate commerce a drug that is a biological product, a valid BLA must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. Your products are not the subject of an approved BLA.\nAdditional Concerns\nIn addition to the violations described above, we have concerns about the following products:\nFDA’s review of your website and other records found that you market additional products, an umbilical cord derived product named Restor Charge and an exosome-based product named Rexo Charge4. Based on our review, these products are drugs and\u002For biological products, which are subject to premarket review and approval requirements. In your response, please provide a customer list for each of these products and indicate whether you believe you sell them in compliance with the FD&C Act. If so, include your explanation why; if not, include your plan for coming into compliance.\nWe also direct your attention to FDA’s Public Safety Notification on Exosome Products, available at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nConclusion\nThis letter is not intended to be an all-inclusive list of deficiencies that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with all applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen (15) working days, please explain the reason for your delay and the timeframe for completion. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration.\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n__________________________\n1 Restor+ is also referred to as restor+, restor, Restor, Restor Plus Wharton’s Jelly, and Restor+ Wharton’s Jelly.\n2 You explained during the inspection that the product Cytosomes was renamed Recyte in 2023 and provided a “Product Update” that states “Cytosomes gets a new name recyte®[.] New name, same quality product.”\n3 Because Restor+, Regain, and Renyte fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\n4 Your Instagram post from December 19, 2024, states that “Restor Charge and Rexo Charge provide strong healing potential at a lower price, making regenerative treatments accessible for everyone.”","New Life Medical Services, LLC","new-life-medical-services-llc-711102-09242025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnew-life-medical-services-llc-711102-09242025","2026-10-26T08:09:32.410522+00:00","2025-10-07","711102","Biologics","Joshua M. Mansavage","2026-08-19T16:15:04.082+00:00","VIA UPS and Electronic Mail","CBER 25-711102","2025-09-24",{"id":97,"raw":98,"subject":59,"body_html":103,"body_text":104,"firm_name":105,"letter_id":106,"created_at":107,"fei_number":19,"letter_url":108,"updated_at":109,"action_type":22,"case_status":23,"posted_date":110,"marcs_cms_no":111,"product_type":49,"closeout_date":19,"issuing_office":112,"recipient_name":113,"body_fetched_at":114,"delivery_method":115,"recipient_title":19,"reference_number":19,"action_taken_date":116,"medical_device_id":19,"response_letter_date":19},2135,[99,100,101,102,59,13,13,13],"\u003Ctime datetime=\"2023-04-18T13:20:00Z\">04\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-04-05T04:00:00Z\">04\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchemical-services-group-incroyal-chemical-company-648378-04052023\">Chemical Services Group, Inc.\u002FRoyal Chemical Company\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Matt Dailey\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO &amp; President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Chemical Services Group, Inc.\u002FRoyal Chemical Company\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8679 South Freeway Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Macedonia\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>44056-1535\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:matt.dailey@royalchemical.com\"> matt.dailey@royalchemical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 648378\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 5, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. Dailey:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Royal Chemical Company, FEI 2517008, at 1336 Crowe Road, East Stroudsburg, Pennsylvania 18301, from October 31 to November 8, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your November 22, 2022 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactured over-the-counter (OTC) hand sanitizer drug products\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on equipment also used to manufacture industrial chemicals, including those for cleaning, polymer production, and paint additives. It is unacceptable as a matter of CGMP to manufacture drugs using the same equipment that you use to manufacture these non-pharmaceutical products due to the risk of cross-contamination. Additionally, your drug component and bulk drug product transfer pipes were found open to the outside environment. Your firm lacked procedures to clean the transfer pipes and external storage tanks.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Confirmation whether you will discontinue manufacturing drugs on shared equipment in your facility. If you intend to continue to manufacture both pharmaceutical and non-pharmaceutical products at your facility, provide a plan to show how you will separate the areas in which you will maintain dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\u003C\u002Fli>\n\t\u003Cli>A risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\u003C\u002Fli>\n\t\u003Cli>For drug product dedicated equipment, a comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment, facility piping, or storage tankers that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\n\t\u003Cli>Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\t\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\t\u003Cli>A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm relied on certificates of analysis (COA) from unqualified suppliers for your ethanol for specifications such as purity, strength, and quality. By not adequately analyzing your components for identity, purity, strength, and quality, you failed to ensure your incoming components meet appropriate specifications.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, you only identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> ethanol suppliers and manufacturers in use. However, in response to FDA’s August 31, 2022 request for records and other information pursuant to section 704(a)(4) of the FD&amp;C Act, you identified \u003Cstrong>(b)(4)\u003C\u002Fstrong> additional suppliers of ethanol.\u003C\u002Fp>\n\n\u003Cp>Furthermore, separate ethanol lots appear to have been co-mingled in a storage tanker for use in hand sanitizer manufacture. The supplier and ethanol lot number are not recorded in your manufacturing records which only list the ethanol source as “bulk.” The lack of supplier testing verification, co-mingling of component lots, and inadequate batch traceability poses a significant risk to consumers and hinders your ability to adequately respond to any ethanol related investigations and product recalls.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Confirmation that ethanol you use as a drug substance meets, at a minimum, the standards delineated in the USP monograph for ethanol.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>Procedures for controlling incoming raw materials including, but not limited to, ensuring that they are not co-mingled. In addition, provide an analysis of storage tanks that held ethanol and bulk hand sanitizer, and whether material from those tanks could have been contaminated via co-mingling or inadequate cleaning.\u003C\u002Fli>\n\t\u003Cli>A list of all ethanol grades, lots, and manufacturers used from January 2022 to the present.\u003C\u002Fli>\n\t\u003Cli>An action plan for any hand sanitizer drug product released to the market manufactured with ethanol that does not comply with USP standards. This plan should include a list of batches, volume distributed, manufacture and expiry dates, and test results.\u003C\u002Fli>\n\t\u003Cli>Controls for maintaining traceability of ethanol lots used in drug product manufacture, including procedures and an updated Master Batch Record.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish acceptance criteria for the sampling and testing conducted by the quality control unit that are adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release (21 CFR 211.165(d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm sampled in process material for the purpose of batch release testing which likewise did not include all appropriate tests to ensure that the finished drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Specifically, batches were \u003Cstrong>(b)(4)\u003C\u002Fstrong> removal from the bulk hand sanitizer and your batch release testing did not include known impurities, such as for methanol and benzene.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A list of chemical and microbiological specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; &nbsp; o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) failed to provide adequate oversight of the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Written procedures for equipment and facility cleaning, monitoring, and cleaning of your water system, vendor qualification, packaging and labeling operations, process validation, and the release of drug products (21 CFR 211.22(d)).\u003C\u002Fli>\n\t\u003Cli>Adequate investigation into high colony counts in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system used to generate component \u003Cstrong>(b)(4)\u003C\u002Fstrong> water for your drug products. (21 CFR 211.192).\u003C\u002Fli>\n\t\u003Cli>Validation of manufacturing processes before release of material to the market (21 CFR 100(a)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The CGMP regulations assign responsibilities to the QU which include approving or rejecting incoming materials, in-process materials, and drug products; ensuring that controls are implemented and completed satisfactorily during manufacturing operations; and reviewing production records and investigating any unexplained discrepancies. You have not demonstrated that you have a QU capable of these responsibilities.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to orapharm1_responses@fda.hhs.gov. Your written notification should refer to the Warning Letter, CMS # 648378 and reference: FEI 2517008.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, contact Compliance Officer CAPT Liatte Closs at liatte.closs@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nOPQO Division I\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nMr. Bryan Benner, Director of Quality\u003Cbr>\nRoyal Chemical Company\u003Cbr>\n1336 Crowe Rd\u003Cbr>\nE Stroudsburg, PA 18301\u003Cbr>\nBryan.Benner@RoyalChemical.com\u003C\u002Fp>\n\n\u003Cp>Mr. Dave DeBord, COO\u003Cbr>\nRoyal Chemical Company\u003Cbr>\n1336 Crowe Rd\u003Cbr>\nE Stroudsburg, PA 18301\u003Cbr>\ndave.debord@royalchemical.com\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (\u003Cstrong>86 Fed Reg at 56960\u003C\u002Fstrong>). This guidance communicated the agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because Royal Chemical Company hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Matt Dailey\n\nRecipient Title\n\nCEO & President\n\nChemical Services Group, Inc.\u002FRoyal Chemical Company\n\n8679 South Freeway Drive\n\nMacedonia, OH 44056-1535\n\nUnited States\n\nmatt.dailey@royalchemical.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWARNING LETTER\n\nCMS # 648378\n\nApril 5, 2023\n\nDear Mr. Dailey:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Royal Chemical Company, FEI 2517008, at 1336 Crowe Road, East Stroudsburg, Pennsylvania 18301, from October 31 to November 8, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your November 22, 2022 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\n\nYour firm manufactured over-the-counter (OTC) hand sanitizer drug products1 on equipment also used to manufacture industrial chemicals, including those for cleaning, polymer production, and paint additives. It is unacceptable as a matter of CGMP to manufacture drugs using the same equipment that you use to manufacture these non-pharmaceutical products due to the risk of cross-contamination. Additionally, your drug component and bulk drug product transfer pipes were found open to the outside environment. Your firm lacked procedures to clean the transfer pipes and external storage tanks.\n\nIn response to this letter, provide:\n\nConfirmation whether you will discontinue manufacturing drugs on shared equipment in your facility. If you intend to continue to manufacture both pharmaceutical and non-pharmaceutical products at your facility, provide a plan to show how you will separate the areas in which you will maintain dedicated manufacturing equipment for your pharmaceutical manufacturing and industrial product manufacturing operations.\n\nA risk assessment for all drugs you have previously produced on equipment shared with industrial products. For each product, assess the risk of potential contamination due to the shared equipment, and provide your plans for addressing the product quality and patient safety risks for any product still in distribution, including potential recalls or market withdrawals.\n\nFor drug product dedicated equipment, a comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment, facility piping, or storage tankers that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\n\nYour corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\nA summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n2. Your firm failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(2)).\n\nYour firm relied on certificates of analysis (COA) from unqualified suppliers for your ethanol for specifications such as purity, strength, and quality. By not adequately analyzing your components for identity, purity, strength, and quality, you failed to ensure your incoming components meet appropriate specifications.\n\nAdditionally, during the inspection, you only identified (b)(4) ethanol suppliers and manufacturers in use. However, in response to FDA’s August 31, 2022 request for records and other information pursuant to section 704(a)(4) of the FD&C Act, you identified (b)(4) additional suppliers of ethanol.\n\nFurthermore, separate ethanol lots appear to have been co-mingled in a storage tanker for use in hand sanitizer manufacture. The supplier and ethanol lot number are not recorded in your manufacturing records which only list the ethanol source as “bulk.” The lack of supplier testing verification, co-mingling of component lots, and inadequate batch traceability poses a significant risk to consumers and hinders your ability to adequately respond to any ethanol related investigations and product recalls.\n\nIn response to this letter, provide:\n\nConfirmation that ethanol you use as a drug substance meets, at a minimum, the standards delineated in the USP monograph for ethanol.\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nProcedures for controlling incoming raw materials including, but not limited to, ensuring that they are not co-mingled. In addition, provide an analysis of storage tanks that held ethanol and bulk hand sanitizer, and whether material from those tanks could have been contaminated via co-mingling or inadequate cleaning.\n\nA list of all ethanol grades, lots, and manufacturers used from January 2022 to the present.\n\nAn action plan for any hand sanitizer drug product released to the market manufactured with ethanol that does not comply with USP standards. This plan should include a list of batches, volume distributed, manufacture and expiry dates, and test results.\n\nControls for maintaining traceability of ethanol lots used in drug product manufacture, including procedures and an updated Master Batch Record.\n\n3. Your firm failed to establish acceptance criteria for the sampling and testing conducted by the quality control unit that are adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release (21 CFR 211.165(d)).\n\nYour firm sampled in process material for the purpose of batch release testing which likewise did not include all appropriate tests to ensure that the finished drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Specifically, batches were (b)(4) removal from the bulk hand sanitizer and your batch release testing did not include known impurities, such as for methanol and benzene.\n\nIn response to this letter, provide:\n\nA list of chemical and microbiological specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\n\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) failed to provide adequate oversight of the manufacture of your OTC drug products. For example, your QU failed to ensure the following:\n\nWritten procedures for equipment and facility cleaning, monitoring, and cleaning of your water system, vendor qualification, packaging and labeling operations, process validation, and the release of drug products (21 CFR 211.22(d)).\n\nAdequate investigation into high colony counts in your (b)(4) system used to generate component (b)(4) water for your drug products. (21 CFR 211.192).\n\nValidation of manufacturing processes before release of material to the market (21 CFR 100(a)).\n\nThe CGMP regulations assign responsibilities to the QU which include approving or rejecting incoming materials, in-process materials, and drug products; ensuring that controls are implemented and completed satisfactorily during manufacturing operations; and reviewing production records and investigating any unexplained discrepancies. You have not demonstrated that you have a QU capable of these responsibilities.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.2 Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to orapharm1_responses@fda.hhs.gov. Your written notification should refer to the Warning Letter, CMS # 648378 and reference: FEI 2517008.\n\nIf you have any questions, contact Compliance Officer CAPT Liatte Closs at liatte.closs@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nU.S. Food and Drug Administration\n\nOPQO Division I\n\nCC:\n\nMr. Bryan Benner, Director of Quality\n\nRoyal Chemical Company\n\n1336 Crowe Rd\n\nE Stroudsburg, PA 18301\n\nBryan.Benner@RoyalChemical.com\n\nMr. Dave DeBord, COO\n\nRoyal Chemical Company\n\n1336 Crowe Rd\n\nE Stroudsburg, PA 18301\n\ndave.debord@royalchemical.com\n\n______________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). This guidance communicated the agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. Because Royal Chemical Company hand sanitizer drug products were not consistent with the formulations described in these guidances, they did not fall within any temporary agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.\n\n2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Chemical Services Group, Inc.\u002FRoyal Chemical Company","chemical-services-group-incroyal-chemical-company-648378-04052023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchemical-services-group-incroyal-chemical-company-648378-04052023","2026-10-26T08:08:14.181719+00:00","2023-04-18","648378","Division of Pharmaceutical Quality Operations I","Mr. Matt Dailey","2026-08-20T01:09:28.248+00:00","VIA UPS","2023-04-05",{"id":118,"raw":119,"subject":59,"body_html":124,"body_text":125,"firm_name":126,"letter_id":127,"created_at":107,"fei_number":19,"letter_url":128,"updated_at":129,"action_type":22,"case_status":23,"posted_date":130,"marcs_cms_no":131,"product_type":49,"closeout_date":19,"issuing_office":123,"recipient_name":132,"body_fetched_at":133,"delivery_method":134,"recipient_title":19,"reference_number":19,"action_taken_date":135,"medical_device_id":19,"response_letter_date":19},2412,[120,121,122,123,59,13,13,13],"\u003Ctime datetime=\"2022-10-04T13:20:00Z\">10\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-27T04:00:00Z\">09\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsterling-pharmaceutical-services-llc-629019-09272022\">Sterling Pharmaceutical Services, LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations III","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert T. Flynn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sterling Pharmaceutical Services, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>109 S 2nd St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dupo\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>62239\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 27, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL #629019\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Flynn:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sterling Pharmaceutical Services, LLC, FEI 3009705561, at 109 S 2nd Street, Dupo, Illinois, from February 7 to 18, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, the FDA reviewed the product labels for \u003Cstrong>(b)(4)\u003C\u002Fstrong> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” collected during an inspection of your facility between February 7, 2022 and February 18, 2022. Based on our review, these products are unapproved new drugs under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355. Introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d), 355(a). In addition, your firm has significant violations of CGMP regulations. Your firm’s poor manufacturing practices are particularly concerning because many of your products, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” are ophthalmic and directed for use in young children.\u003Cbr>\n\u003Cbr>\nWe reviewed your March 14, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a contract manufacturer of sterile over-the-counter and homeopathic ophthalmic drug products utilizing aseptic processing. You identified your aseptic processing lines as Restricted Access Barrier Systems (RABS). However, your systems permitted access to the processing line (e.g., use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>) without the design of rigid wall enclosures. Furthermore, you lacked other fundamental elements of a valid RABS design including glove ports which are employed to reduce or eliminate direct operator interventions into the ISO 5 critical area. These glove ports and infrequent door openings provide the foundation for the overall design and control concept of a RABS that reduces the hazard of ingress of contamination from the surrounding aseptic processing cleanroom environment. Your processing lines lacked basic design features to enable them to be categorized as a RABS.\u003C\u002Fp>\n\n\u003Cp>You did not adequately investigate the excursions above your action limit, including an adverse trend of microbiological contamination from your aseptic processing line environment. For example, from January 1 to December 31, 2021, your environmental monitoring (EM) program repeatedly recovered microorganisms from production line ISO 5 areas (air, surface, and personnel) in your facility.\u003C\u002Fp>\n\n\u003Cp>Your EM results from January 1 to February 16, 2022, including ISO 5 areas and aseptic processing operator glove samples, showed an adverse trend that revealed compromised environmental control of your aseptic processing operation. You continued ophthalmic drug production without adequate investigation and preventive measures to address the persistent microbiological contamination in your ISO 5 environments that posed a risk to product sterility.\u003C\u002Fp>\n\n\u003Cp>Specific incident investigations into these contamination risks routinely identified poor aseptic behavior by personnel and concluded there was a “very low” risk to drug products. Your investigations were inadequate because they did not thoroughly address the persistent adverse trend of microorganisms recovered from ISO 5 areas, including spore-forming bacteria and fungi.\u003C\u002Fp>\n\n\u003Cp>Environmental monitoring of your cleanrooms also recovered gram negative bacterial contamination.\u003C\u002Fp>\n\n\u003Cp>Moreover, on July 7, 2021, your firm detected a sterility failure for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, contaminated with \u003Cem>Herbaspirillum aquaticum\u003C\u002Fem>, a gram-negative bacterium. Non-sterile ophthalmic drugs pose unacceptable risks to patients. We acknowledge that you rejected this lot, however your investigation failed to consider that this sterility failure, in conjunction with your adverse EM trends, may be indicative of contamination risks from the basic design of your processing lines and could impact other batches.\u003C\u002Fp>\n\n\u003Cp>It should be noted that a sterility test, while a critical quality control for aseptically processed products that purport to be sterile, cannot be solely relied upon as justification to release drug product batches as the test is only the last in a series of design provisions and controls intended to protect the consumer from distribution of an unsafe batch. Any finished product positive sterility test results represent a serious CGMP issue requiring prompt and comprehensive investigation. Furthermore, your firm’s absence of strict adherence to proper design, aseptic methods, and environmental controls undermine your daily assurance of consistent sterile manufacturing.\u003C\u002Fp>\n\n\u003Cp>In your response you indicate that you conducted a retrospective evaluation of all microbiological monitoring results between January 2021, and March 2022, and concluded that there was no impact to the lots previously released. Your response is inadequate as your retrospective review relied on third-party sterility testing, smoke studies, personnel training, and processes, but failed to consider that persistently deficient environmental controls are likely rooted in fundamental facility or equipment design flaws. In addition to line design hazards that fundamentally compromise aseptic processing, you performed makeshift line modification within the ISO 5 areas using materials that can harbor bioburden (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\n\n\u003Cp>A vigilant ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities including, but not be limited to:\u003Cbr>\n&nbsp; o All human interactions with the ISO 5 area\u003Cbr>\n&nbsp; o Equipment placement and suitability, including ergonomics for each human interaction\u003Cbr>\n&nbsp; o Air quality in the ISO 5 area, and surrounding room including, but not limited to, air volume, air flow, and microbial\u002Fparticulate levels\u003Cbr>\n&nbsp; o Facility layout\u003Cbr>\n&nbsp; o Personnel flows and material flows throughout all rooms used to support and conduct sterile operations\u003Cbr>\n&nbsp; o Building management systems\u003C\u002Fp>\n\n\u003Cp>• A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA will robustly remediate your deficient sterile manufacturing operation. Include comprehensive changes\u002Fimprovements in the design of both your aseptic processing lines and cleanrooms. Also describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fp>\n\n\u003Cp>• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, timely upgrades to equipment and facilities, adherence to appropriate preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive and independent assessment of your ongoing use of a rapid sterility testing method for ophthalmic drug products produced on an aseptic line that requires frequent human intervention. Include the independent assessment to evaluate whether the method is equivalent to or better than USP &lt;71&gt; sterility test.\u003C\u002Fp>\n\n\u003Cp>• A summary of your program for qualifying and overseeing the contract laboratory performing testing of drug products you manufacture. Include a detailed assessment to determine if the laboratory is qualified to do the tests and all batch testing performed on your behalf is satisfactory.\u003C\u002Fp>\n\n\u003Cp>• A summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, sterility testing via compendial method of each batch. If testing yields an out of specification result or unexplained discrepancy, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fp>\n\n\u003Cp>• An independent assessment of your EM program including, but not limited to, investigating deviations from microbiological limits. Include your plan for implementing the recommendations in the assessment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your EM program (including personnel monitoring) was inadequate for classified areas used for the production of sterile ophthalmic drug products. We observed instances during production of two lots of sterile eye drops in which your firm failed to ensure adequate monitoring of non-viable particulates (NVP).\u003C\u002Fp>\n\n\u003Cp>Furthermore, personnel monitoring was insufficient. Monitoring was limited to operators’ gloved hands following aseptic interventions. Because of the significant gaps within your EM program, you have insufficient information to assess the quality of the aseptic processing environment.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you did not provide the recovered NVP data and describe how you recovered the data (which you stated during the inspection was unrecoverable). You also did not determine how many batches may have been affected by your identified root cause.\u003C\u002Fp>\n\n\u003Cp>Further, your response indicated that you made procedural changes to incorporate occasional monitoring of arms and hoods of personnel gowns based on your risk assessment (V22-00602.RA). However, your response is inadequate because it fails to consider potential basic design issues with your aseptic processing line as supported by the nature and frequency of personnel aseptic interventions, manually intensive activities, EM data, aseptic breaches, and line maintenance manipulations. For example, in your response, you failed to include justification for omitting samples of personnel goggles and chest as well as aseptic processing line \u003Cstrong>(b)(4)\u003C\u002Fstrong> from EM. Environmental monitoring should promptly identify potential routes of contamination, allowing for implementation of corrections before product contamination could occur.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive independent review of your personnel and EM program, including but not limited to:\u003Cbr>\n&nbsp; o A plan to fully remediate these programs. For example, describe changes to equipment, procedures and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging microbiological trends from your classified areas. Provide an updated timeline for implementation of your improved program, including procedural changes.\u003Cbr>\n&nbsp; o A risk assessment based on a retrospective review of personnel and EM data since you initiated sterile manufacturing of ophthalmic drug products. This assessment should include a review of all batches likely affected by gaps in NVP data.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm had not established adequate procedures designed to prevent microbiological contamination risks in your facility. For example, your firm did not routinely document interventions performed by aseptic processing area operators during production. In addition, our investigators observed poor aseptic behaviors.\u003C\u002Fp>\n\n\u003Cp>Investigators observed operators repeatedly exhibiting poor aseptic behaviors during filling operations of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. To perform interventions during aseptic operations, the design of your filling line required personnel to reach through a \u003Cstrong>(b)(4)\u003C\u002Fstrong> placed in front of the aseptic processing equipment where open processing of finished product occurred. Operators were also observed contacting the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with their goggles and chest area of their gowns while leaning into the ISO 5 zone to perform aseptic interventions. Additionally, operators did not sanitize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong>, although it was required by your procedures for interventions. Among other factors, adequate separation, proper line design and control, robust sterilization and disinfection, a vigilant EM program, and strict personnel adherence to aseptic practices are essential to prevent contamination.\u003C\u002Fp>\n\n\u003Cp>Our investigators also observed that non-routine interventions performed by aseptic operators were not recorded. The exclusion of this data inhibits adequate quality evaluations and investigations into deficiencies and compromises your ability to ensure media fills accurately simulate the number and type of interventions that occur during commercial manufacturing.\u003C\u002Fp>\n\n\u003Cp>Your response includes changes to batch record documentation and procedures for qualification of aseptic operators along with applicable training. However, your response fails to acknowledge potential design issues (e.g., equipment ergonomic flaws that influence operator behaviors), excessive need for manual manipulations, and insufficiency of barrier protection to provide adequate separation from surrounding areas.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to better assure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality assurance oversight (e.g., audit) during aseptic processing and other operations.\u003C\u002Fp>\n\n\u003Cp>• A thorough risk assessment that evaluates how poor aseptic technique and cleanroom behavior, such as those observed during the inspection, may have affected quality and sterility of your drugs.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Statements on the product labels that provide evidence of the intended uses of these products include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> . . . ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Supports: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Ointment\u003C\u002Fstrong>\u003Cbr>\n• The product name “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” which is located together on the label with “Drug Facts . . . Directions . . . \u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> . . . ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Ointment\u003C\u002Fstrong>\u003Cbr>\n• The product name “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” which is located together on the label with “Drug Facts . . . Directions . . . \u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Ointment\u003C\u002Fstrong>\u003Cbr>\n• The product name “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” which is located together on the label with “Drug Facts . . . Directions . . . \u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\n\n\u003Cp>The above claims for \u003Cstrong>(b)(4)\u003C\u002Fstrong> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” demonstrate that they are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Moreover, these products are “new drugs,” as defined by 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these products. Accordingly, these products are unapproved new drugs marketed in violation of sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>We recognize that \u003Cstrong>(b)(4)\u003C\u002Fstrong> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” are labeled as homeopathic drugs with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production operations oversight to ensure reliable facilities and equipment, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge you engaged a consultant to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Guidance on Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Brian D. Garthwaite, Ph. D.\u003Cbr>\nCompliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Case Number above (#629019). If you have questions regarding the contents of this letter, please contact Dr. Garthwaite at (612) 758-7132.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Jeffrey Meng\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRobert T. Flynn\n\nRecipient Title\n\nChief Executive Officer\n\nSterling Pharmaceutical Services, LLC\n\n109 S 2nd St.\n\nDupo, IL 62239\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nSeptember 27, 2022\n\nWARNING LETTER\n\nWL #629019\n\nDear Mr. Flynn:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sterling Pharmaceutical Services, LLC, FEI 3009705561, at 109 S 2nd Street, Dupo, Illinois, from February 7 to 18, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, the FDA reviewed the product labels for (b)(4) “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” and “(b)(4),” collected during an inspection of your facility between February 7, 2022 and February 18, 2022. Based on our review, these products are unapproved new drugs under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355. Introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d), 355(a). In addition, your firm has significant violations of CGMP regulations. Your firm’s poor manufacturing practices are particularly concerning because many of your products, such as (b)(4) “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” and “(b)(4),” are ophthalmic and directed for use in young children.\n\nWe reviewed your March 14, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour firm is a contract manufacturer of sterile over-the-counter and homeopathic ophthalmic drug products utilizing aseptic processing. You identified your aseptic processing lines as Restricted Access Barrier Systems (RABS). However, your systems permitted access to the processing line (e.g., use of (b)(4)) without the design of rigid wall enclosures. Furthermore, you lacked other fundamental elements of a valid RABS design including glove ports which are employed to reduce or eliminate direct operator interventions into the ISO 5 critical area. These glove ports and infrequent door openings provide the foundation for the overall design and control concept of a RABS that reduces the hazard of ingress of contamination from the surrounding aseptic processing cleanroom environment. Your processing lines lacked basic design features to enable them to be categorized as a RABS.\n\nYou did not adequately investigate the excursions above your action limit, including an adverse trend of microbiological contamination from your aseptic processing line environment. For example, from January 1 to December 31, 2021, your environmental monitoring (EM) program repeatedly recovered microorganisms from production line ISO 5 areas (air, surface, and personnel) in your facility.\n\nYour EM results from January 1 to February 16, 2022, including ISO 5 areas and aseptic processing operator glove samples, showed an adverse trend that revealed compromised environmental control of your aseptic processing operation. You continued ophthalmic drug production without adequate investigation and preventive measures to address the persistent microbiological contamination in your ISO 5 environments that posed a risk to product sterility.\n\nSpecific incident investigations into these contamination risks routinely identified poor aseptic behavior by personnel and concluded there was a “very low” risk to drug products. Your investigations were inadequate because they did not thoroughly address the persistent adverse trend of microorganisms recovered from ISO 5 areas, including spore-forming bacteria and fungi.\n\nEnvironmental monitoring of your cleanrooms also recovered gram negative bacterial contamination.\n\nMoreover, on July 7, 2021, your firm detected a sterility failure for (b)(4), lot (b)(4), contaminated with Herbaspirillum aquaticum, a gram-negative bacterium. Non-sterile ophthalmic drugs pose unacceptable risks to patients. We acknowledge that you rejected this lot, however your investigation failed to consider that this sterility failure, in conjunction with your adverse EM trends, may be indicative of contamination risks from the basic design of your processing lines and could impact other batches.\n\nIt should be noted that a sterility test, while a critical quality control for aseptically processed products that purport to be sterile, cannot be solely relied upon as justification to release drug product batches as the test is only the last in a series of design provisions and controls intended to protect the consumer from distribution of an unsafe batch. Any finished product positive sterility test results represent a serious CGMP issue requiring prompt and comprehensive investigation. Furthermore, your firm’s absence of strict adherence to proper design, aseptic methods, and environmental controls undermine your daily assurance of consistent sterile manufacturing.\n\nIn your response you indicate that you conducted a retrospective evaluation of all microbiological monitoring results between January 2021, and March 2022, and concluded that there was no impact to the lots previously released. Your response is inadequate as your retrospective review relied on third-party sterility testing, smoke studies, personnel training, and processes, but failed to consider that persistently deficient environmental controls are likely rooted in fundamental facility or equipment design flaws. In addition to line design hazards that fundamentally compromise aseptic processing, you performed makeshift line modification within the ISO 5 areas using materials that can harbor bioburden (e.g., (b)(4)).\n\nA vigilant ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities including, but not be limited to:\n\no All human interactions with the ISO 5 area\n\no Equipment placement and suitability, including ergonomics for each human interaction\n\no Air quality in the ISO 5 area, and surrounding room including, but not limited to, air volume, air flow, and microbial\u002Fparticulate levels\n\no Facility layout\n\no Personnel flows and material flows throughout all rooms used to support and conduct sterile operations\n\no Building management systems\n\n• A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA will robustly remediate your deficient sterile manufacturing operation. Include comprehensive changes\u002Fimprovements in the design of both your aseptic processing lines and cleanrooms. Also describe your plans for qualification and validation of your extensively remediated operations.\n\n• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, timely upgrades to equipment and facilities, adherence to appropriate preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review.\n\n• A comprehensive and independent assessment of your ongoing use of a rapid sterility testing method for ophthalmic drug products produced on an aseptic line that requires frequent human intervention. Include the independent assessment to evaluate whether the method is equivalent to or better than USP \u003C71> sterility test.\n\n• A summary of your program for qualifying and overseeing the contract laboratory performing testing of drug products you manufacture. Include a detailed assessment to determine if the laboratory is qualified to do the tests and all batch testing performed on your behalf is satisfactory.\n\n• A summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, sterility testing via compendial method of each batch. If testing yields an out of specification result or unexplained discrepancy, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n\n• An independent assessment of your EM program including, but not limited to, investigating deviations from microbiological limits. Include your plan for implementing the recommendations in the assessment.\n\n2. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n\nYour EM program (including personnel monitoring) was inadequate for classified areas used for the production of sterile ophthalmic drug products. We observed instances during production of two lots of sterile eye drops in which your firm failed to ensure adequate monitoring of non-viable particulates (NVP).\n\nFurthermore, personnel monitoring was insufficient. Monitoring was limited to operators’ gloved hands following aseptic interventions. Because of the significant gaps within your EM program, you have insufficient information to assess the quality of the aseptic processing environment.\n\nYour response is inadequate because you did not provide the recovered NVP data and describe how you recovered the data (which you stated during the inspection was unrecoverable). You also did not determine how many batches may have been affected by your identified root cause.\n\nFurther, your response indicated that you made procedural changes to incorporate occasional monitoring of arms and hoods of personnel gowns based on your risk assessment (V22-00602.RA). However, your response is inadequate because it fails to consider potential basic design issues with your aseptic processing line as supported by the nature and frequency of personnel aseptic interventions, manually intensive activities, EM data, aseptic breaches, and line maintenance manipulations. For example, in your response, you failed to include justification for omitting samples of personnel goggles and chest as well as aseptic processing line (b)(4) from EM. Environmental monitoring should promptly identify potential routes of contamination, allowing for implementation of corrections before product contamination could occur.\n\nIn response to this letter, provide:\n\n• A comprehensive independent review of your personnel and EM program, including but not limited to:\n\no A plan to fully remediate these programs. For example, describe changes to equipment, procedures and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging microbiological trends from your classified areas. Provide an updated timeline for implementation of your improved program, including procedural changes.\n\no A risk assessment based on a retrospective review of personnel and EM data since you initiated sterile manufacturing of ophthalmic drug products. This assessment should include a review of all batches likely affected by gaps in NVP data.\n\n3. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nYour firm had not established adequate procedures designed to prevent microbiological contamination risks in your facility. For example, your firm did not routinely document interventions performed by aseptic processing area operators during production. In addition, our investigators observed poor aseptic behaviors.\n\nInvestigators observed operators repeatedly exhibiting poor aseptic behaviors during filling operations of (b)(4), Lot (b)(4). To perform interventions during aseptic operations, the design of your filling line required personnel to reach through a (b)(4) placed in front of the aseptic processing equipment where open processing of finished product occurred. Operators were also observed contacting the (b)(4) with their goggles and chest area of their gowns while leaning into the ISO 5 zone to perform aseptic interventions. Additionally, operators did not sanitize the (b)(4) with sterile (b)(4), although it was required by your procedures for interventions. Among other factors, adequate separation, proper line design and control, robust sterilization and disinfection, a vigilant EM program, and strict personnel adherence to aseptic practices are essential to prevent contamination.\n\nOur investigators also observed that non-routine interventions performed by aseptic operators were not recorded. The exclusion of this data inhibits adequate quality evaluations and investigations into deficiencies and compromises your ability to ensure media fills accurately simulate the number and type of interventions that occur during commercial manufacturing.\n\nYour response includes changes to batch record documentation and procedures for qualification of aseptic operators along with applicable training. However, your response fails to acknowledge potential design issues (e.g., equipment ergonomic flaws that influence operator behaviors), excessive need for manual manipulations, and insufficiency of barrier protection to provide adequate separation from surrounding areas.\n\nIn response to this letter, provide:\n\n• Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to better assure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality assurance oversight (e.g., audit) during aseptic processing and other operations.\n\n• A thorough risk assessment that evaluates how poor aseptic technique and cleanroom behavior, such as those observed during the inspection, may have affected quality and sterility of your drugs.\n\nUnapproved New Drugs\n\nStatements on the product labels that provide evidence of the intended uses of these products include, but are not limited to, the following:\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) . . . ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Supports: ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Ointment\n\n• The product name “(b)(4),” which is located together on the label with “Drug Facts . . . Directions . . . (b)(4).”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) . . . ● (b)(4)”\n\n“(b)(4)” Sterile Eye Ointment\n\n• The product name “(b)(4),” which is located together on the label with “Drug Facts . . . Directions . . . (b)(4).”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Ointment\n\n• The product name “(b)(4),” which is located together on the label with “Drug Facts . . . Directions . . . (b)(4).”\n\nThe above claims for (b)(4) “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” and “(b)(4)” demonstrate that they are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Moreover, these products are “new drugs,” as defined by 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these products. Accordingly, these products are unapproved new drugs marketed in violation of sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nWe recognize that (b)(4) “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” and “(b)(4)” are labeled as homeopathic drugs with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or approval.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production operations oversight to ensure reliable facilities and equipment, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nCGMP Consultant Recommended\n\nWe acknowledge you engaged a consultant to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nAdditional Guidance on Aseptic Processing\n\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Brian D. Garthwaite, Ph. D.\n\nCompliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nYour written notification should refer to the Warning Letter Case Number above (#629019). If you have questions regarding the contents of this letter, please contact Dr. Garthwaite at (612) 758-7132.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Jeffrey Meng\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations III\n\ncc: (b)(4)","Sterling Pharmaceutical Services, LLC","sterling-pharmaceutical-services-llc-629019-09272022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsterling-pharmaceutical-services-llc-629019-09272022","2026-10-26T08:10:05.992438+00:00","2022-10-04","629019","Robert T. Flynn","2026-08-20T01:31:42.647+00:00","UPS Next Day","2022-09-27",6,{"510k":138,"classification":139,"enforcement":140,"event":141,"event_backfill":142,"pma":143,"warning_letter":144},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]